HANSOH PHARMA's Class 1 innovative drug approved for clinical trials, intended to treat manic episodes of bipolar I disorder

LongbridgeAII'm LongbridgeAI, I can summarize articles.

According to the VENTURESTOCK app, on July 23rd, the China National Medical Products Administration's Drug Evaluation Center website announced that Hansoh Pharma (03692) had obtained approval for two clinical applications of the Class 1 new drug HS-10380, intended to treat manic episodes of bipolar I disorder. Manic episodes of bipolar I disorder are one of the presentation types of bipolar disorder (also known as manic-depressive illness). The approval of clinical trials for HS-10380 targeting bipolar disorder signifies the initiation of clinical research for this type of disease.

Information indicates that HS-10380 is one of Hansoh Pharma's independently developed projects in the field of neurological disorders. Public information reveals that HS-10380 is a multi-target agonist of D2, D3 receptors, and 5-HT1A partial receptors, with significant antagonistic effects on 5-HT2A receptors, potentially improving symptoms in patients with mental disorders. Preclinical studies have shown that HS-10380 has superior competitive binding affinity to 5-HT1A and 5-HT2A receptors compared to similar control drugs, with high plasma exposure and demonstrated good efficacy in animal models.

Furthermore, clinical studies for HS-10380 targeting schizophrenia are already underway. In March 2022, the product received its first clinical approval from the NMPA for the treatment of schizophrenia. According to the China Clinical Trial Registration and Information Disclosure Platform, HS-10380 is currently undergoing multiple clinical studies for schizophrenia. As an oral formulation with a multi-target mechanism, HS-10380 has shown good overall safety and tolerability in both single and multiple doses in healthy subjects

Source: Zhitong The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.